EU-funded researchers gain insights into genetics of lung functioning

A large-scale study has identified five new genetic loci (points on the genome) associated with the health of the human lung and pulmonary function. Publishing in the latest edition of the journal Nature Genetics, the partly EU-funded researchers explain that their findings shed new light on the molecular basis of lung disease and might lead to better treatment of chronic obstructive pulmonary disease (COPD), asthma and similar conditions.

The researchers studied samples from more than 20,000 people, mapping specific loci linked to two clinically relevant measures of lung function. Those measures are forced expiratory volume in the first second (FEV1), which represents the amount of air that can be exhaled in the first second, and the ratio of FEV1 to forced vital capacity (FVC). FVC stands for the amount of air that can be exhaled after full inspiration.

From a clinical point of view, both measures are important indicators of population morbidity and mortality and form the diagnostic basis for COPD. It is also a well-known fact that pulmonary function is in part determined by genetic factors. The research, conducted by 96 scientists in Europe and Australia and led by Dr Martin Tobin of the University of Leicester, UK, and the University of Nottingham's Professor Ian Hall, pinpointed five genetic loci that play a role in the functioning of the lungs. These loci were observed in the whole population and were not specific to smokers, for instance.

In addition, three of the loci were also identified in a second study, published in the same edition of Nature Genetics. The work of the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) consortium is based on a different, but equally large set of samples and thus corroborates some of the findings of Dr Tobin and his colleagues.

"This work is important because until now we have known very little about the genetic factors that determine an individual's lung function," the researchers say. "By identifying the genes important in determining lung function, we can start to unravel the underlying mechanisms which control both lung development and lung damage. This will lead to a better understanding of diseases such as ... COPD and asthma. Crucially, it could open up new opportunities to manage and treat patients with lung conditions."

The scientists add: "A large reduction in lung function occurs in ... COPD, which affects around 1 in 10 adults above the age of 40 and is thought to be the 4th most common cause of death worldwide. Smoking is the major risk factor for development of COPD. Lung function and COPD cluster within families, indicating that variations in genes also predispose individuals to reduced lung function."

Both studies were partly funded by the EU through the following projects: EURO BLCS (Biological, clinical and genetic markers of future risk of cardiovascular disease) and GENOMEUTWIN (Genome-wide analyses of European twin and population cohorts to identify genes in common diseases), both funded under the Fifth Framework Programme (FP5); GABRIEL (A multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community) and EUROSPAN (European special populations research network: quantifying and harnessing genetic variation for gene discovery), both supported through the Sixth Framework Programme (FP6); and GEFOS (Genetic factors for osteoporosis), a project that is part of the Seventh Framework Programme (FP7).

For further information, please visit:

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...